PD-1/PD-L1免疫治疗:对抗乳腺癌耐药

G. Antony, Sulfath Thottungal Parambil, Ajeesh Babu Littleflower, Lakshmi Subhadradevi
{"title":"PD-1/PD-L1免疫治疗:对抗乳腺癌耐药","authors":"G. Antony, Sulfath Thottungal Parambil, Ajeesh Babu Littleflower, Lakshmi Subhadradevi","doi":"10.26420/austinjclinimmunol.2023.1051","DOIUrl":null,"url":null,"abstract":"In recent years, immune-checkpoint blocking therapy targeting the PD-1/PD-L1 axis has advanced tumor immunotherapy to a new level, with positive outcomes in a variety of malignant tumors. Tumors can avoid an antigen-specific T cell immune response by means of PD-1/PD-L1 signaling, which adversely controls T cell-mediated immune response. In clinical practice, it was shown that while some patients did have long-term success with immunotherapy, the majority eventually had resistance to drugs and recurrence. Hence, one of the main challenges that severely restricts the long-lasting benefits and widespread use of PD-1/PD-L1 blocking treatment is both primary and acquired resistance. Therefore, it is high time to understand the mechanisms of resistance for improving anti-PD-1/PD-L1 efficacy. In this review, we describe major signaling pathways that regulate PD-1/PD-L1 axis in cancers as well as the role of PD-1/PD-L1 in breast cancer development and progression. In addition, we further discuss the involvement of PD-1/PD-L1 axis in multi-drug resistance in cancers, which affected breast cancer and other solid tumor response rates and durability to treatment strategies.","PeriodicalId":90446,"journal":{"name":"Austin journal of clinical immunology","volume":"74 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PD-1/PD-L1 Immunotherapy: Combating Drug Resistance in Breast Cancer\",\"authors\":\"G. Antony, Sulfath Thottungal Parambil, Ajeesh Babu Littleflower, Lakshmi Subhadradevi\",\"doi\":\"10.26420/austinjclinimmunol.2023.1051\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In recent years, immune-checkpoint blocking therapy targeting the PD-1/PD-L1 axis has advanced tumor immunotherapy to a new level, with positive outcomes in a variety of malignant tumors. Tumors can avoid an antigen-specific T cell immune response by means of PD-1/PD-L1 signaling, which adversely controls T cell-mediated immune response. In clinical practice, it was shown that while some patients did have long-term success with immunotherapy, the majority eventually had resistance to drugs and recurrence. Hence, one of the main challenges that severely restricts the long-lasting benefits and widespread use of PD-1/PD-L1 blocking treatment is both primary and acquired resistance. Therefore, it is high time to understand the mechanisms of resistance for improving anti-PD-1/PD-L1 efficacy. In this review, we describe major signaling pathways that regulate PD-1/PD-L1 axis in cancers as well as the role of PD-1/PD-L1 in breast cancer development and progression. In addition, we further discuss the involvement of PD-1/PD-L1 axis in multi-drug resistance in cancers, which affected breast cancer and other solid tumor response rates and durability to treatment strategies.\",\"PeriodicalId\":90446,\"journal\":{\"name\":\"Austin journal of clinical immunology\",\"volume\":\"74 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Austin journal of clinical immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26420/austinjclinimmunol.2023.1051\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Austin journal of clinical immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26420/austinjclinimmunol.2023.1051","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

近年来,针对PD-1/PD-L1轴的免疫检查点阻断疗法将肿瘤免疫治疗提升到一个新的水平,在多种恶性肿瘤中取得了积极的效果。肿瘤可以通过PD-1/PD-L1信号传导来避免抗原特异性T细胞免疫反应,而PD-1/PD-L1信号传导对T细胞介导的免疫反应具有不利的控制作用。在临床实践中,虽然一些患者通过免疫治疗确实取得了长期的成功,但大多数患者最终产生了耐药性和复发。因此,严重限制PD-1/PD-L1阻断治疗长期获益和广泛使用的主要挑战之一是原发性和获得性耐药。因此,了解耐药机制以提高抗pd -1/PD-L1的疗效是当务之急。本文综述了肿瘤中PD-1/PD-L1轴调控的主要信号通路,以及PD-1/PD-L1在乳腺癌发生发展中的作用。此外,我们进一步讨论了PD-1/PD-L1轴在癌症多药耐药中的作用,这影响了乳腺癌和其他实体肿瘤对治疗策略的反应率和持久性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
PD-1/PD-L1 Immunotherapy: Combating Drug Resistance in Breast Cancer
In recent years, immune-checkpoint blocking therapy targeting the PD-1/PD-L1 axis has advanced tumor immunotherapy to a new level, with positive outcomes in a variety of malignant tumors. Tumors can avoid an antigen-specific T cell immune response by means of PD-1/PD-L1 signaling, which adversely controls T cell-mediated immune response. In clinical practice, it was shown that while some patients did have long-term success with immunotherapy, the majority eventually had resistance to drugs and recurrence. Hence, one of the main challenges that severely restricts the long-lasting benefits and widespread use of PD-1/PD-L1 blocking treatment is both primary and acquired resistance. Therefore, it is high time to understand the mechanisms of resistance for improving anti-PD-1/PD-L1 efficacy. In this review, we describe major signaling pathways that regulate PD-1/PD-L1 axis in cancers as well as the role of PD-1/PD-L1 in breast cancer development and progression. In addition, we further discuss the involvement of PD-1/PD-L1 axis in multi-drug resistance in cancers, which affected breast cancer and other solid tumor response rates and durability to treatment strategies.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信